Firms
Theme

HALO

Halozyme Therapeutics, Inc. · NASDAQ

$125.63USDCS band Mixed

↑ $1.09 (0.88%)

Last close · Oct 23, 4:00 PM ET

Sign up free to see this.

Mkt Cap
$14.3B
Volume
1.3M
52W High
$126.23
52W Low
$61.23
PE Ratio
34.5
Avg Vol
2.6M
As of 10/23/26
Div Yield
—
Beta
0.48
As of 10/23/26

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Sentiment

No sentiment yet

At least 5 tagged posts are needed.

How do you feel about HALO?

Latest news

News ›

Zacks Investment Research

The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics

Zacks highlights five non-tech Nasdaq stocks with Zacks Rank #1 (Strong Buy) ratings positioned for Q4 gains. Ross Stores benefits from strong sales momentum and store expansion; Roku capitalizes on the shift from linear TV to streaming advertising; APA Corp offers favorable capital efficiency and long-term growth; Corcept Therapeutics sees strong demand for Korlym and new product launches; Halozyme benefits from collaboration royalties and milestone payments.

Zacks Investment Research

Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron

Zacks.com highlights five stocks showing strong relative price strength and outperforming the S&P 500: Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions Holdings, Permian Resources, and Chevron Corp. The article recommends focusing on stocks with consistent outperformance, solid fundamentals, and positive earnings estimate revisions in the current volatile market environment.

Zacks Investment Research

5 Stocks to Buy Using the Relative Price Strength Strategy

U.S. equities remain resilient despite AI-linked tech weakness, with sector rotation indicating broader market strength. The article recommends a relative price strength strategy to identify stocks outperforming the S&P 500 with solid fundamentals and positive earnings revisions. Five stocks highlighted include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions Holdings, Permian Resources, and Chevron Corporation.

Headlines link to the publisher. Not investment advice.

Board · 0 threads

Open board ›

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $HALO · 0 threads

Sign in to post on $HALO

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev